AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders Read the full story

AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies Read the full story

AbbVie has acquired a small molecule active pharmaceutical ingredient (API) manufacturing site in Singapore's Tuas Biomedical Park Read the full story

ENTEROME Bioscience has entered into a collaborative development agreement with AbbVie Read the full story

In response to recent changes to the U.S. tax code to discourage so-called tax inversion deals, Chicago-based AbbVie recently indicated it was rethinking its $54 billion takeover bid of U.K.-based Shire. Read the full story

Shire has finally agreed for an m&a agreement with AbbVie for $54 billion. Read the full story

Abbvie, a top global biopharmaceutical company headquartered in the United States, focusses on solving threatening health problems. A recently formed company in 2013, Abbvie was formed as a separate research based pharma company from Abbott. Read the full story

Abbvie has acquired only one company in 2010 with the purchase of Facet Biotechnology valued at $722 million. Read the full story

Shire rejects Abbvie's $46 billion bid for acquisition. Read the full story